Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Novaferon - Genova Biotech Company

Drug Profile

Novaferon - Genova Biotech Company

Alternative Names: Recombinant anti-tumour and anti-virus protein - Genova Biotech

Latest Information Update: 03 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genova Biotech Company
  • Developer Genova Biotech Company; M. D. Anderson Cancer Center; National Cancer Institute (USA); The Affiliated Hospital of the Chinese Academy of Military Medical Science
  • Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
  • Mechanism of Action Interferon replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III COVID 2019 infections
  • Phase II/III Colorectal cancer
  • Phase II Hepatitis B
  • Phase I/II Liver cancer
  • No development reported Neuroendocrine tumours; Pancreatic cancer

Most Recent Events

  • 28 Oct 2021 Phase-III clinical trials in COVID-2019 infections in Japan (Inhalation) (NCT05172037)
  • 08 Sep 2021 No development reported - Phase-II for Neuroendocrine tumours (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in China (Parenteral)
  • 08 Sep 2021 No development reported - Phase-II for Pancreatic cancer (Late-stage disease, Second-line therapy or greater) in China (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top